$42.29
0.45[1.08%]
Last update: 11:29AM Get Real Time Here
Ionis Pharmaceuticals
(NASDAQ:IONS)Ionis Pharmaceuticals Stock (NASDAQ:IONS), Analyst Ratings, Price Targets, Predictions
Ionis Pharmaceuticals Inc has a consensus price target of $47.71, established from looking at the 69 latest analyst ratings. The last 3 analyst ratings were released from Wolfe Research, Oppenheimer, and Needham on April 10, 2024, April 9, 2024, and April 9, 2024. With an average price target of $45 between Wolfe Research, Oppenheimer, and Needham, there's an implied 7.91% upside for Ionis Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Wolfe Research
Oppenheimer
Needham
Piper Sandler
JP Morgan
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Ionis Pharmaceuticals
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/10/2024 | IONS | Buy Now | Ionis Pharmaceuticals | $41.70 | — | Wolfe Research | Andy Chen | — | Upgrade | Peer Perform → Outperform | Get Alert |
| 04/09/2024 | IONS | Buy Now | Ionis Pharmaceuticals | $41.70 | 79.86% | Oppenheimer | Jay Olson | $72 → $75 | Maintains | Outperform | Get Alert |
| 04/09/2024 | IONS | Buy Now | Ionis Pharmaceuticals | $41.70 | 43.88% | Needham | Joseph Stringer | → $60 | Reiterates | Buy → Buy | Get Alert |
| 03/06/2024 | IONS | Buy Now | Ionis Pharmaceuticals | $41.70 | 72.66% | Oppenheimer | Jay Olson | $65 → $72 | Maintains | Outperform | Get Alert |
| 02/26/2024 | IONS | Buy Now | Ionis Pharmaceuticals | $41.70 | 55.88% | Oppenheimer | Jay Olson | $63 → $65 | Reinstates | → Outperform | Get Alert |
| 02/22/2024 | IONS | Buy Now | Ionis Pharmaceuticals | $41.70 | 51.08% | Piper Sandler | Do Kim | $62 → $63 | Maintains | Overweight | Get Alert |
| 02/22/2024 | IONS | Buy Now | Ionis Pharmaceuticals | $41.70 | 43.88% | Needham | Joseph Stringer | → $60 | Reiterates | Buy → Buy | Get Alert |
| 02/01/2024 | IONS | Buy Now | Ionis Pharmaceuticals | $41.70 | 31.89% | JP Morgan | Jessica Fye | $52 → $55 | Maintains | Neutral | Get Alert |
| 01/26/2024 | IONS | Buy Now | Ionis Pharmaceuticals | $41.70 | 67.87% | RBC Capital | Luca Issi | $65 → $70 | Maintains | Outperform | Get Alert |
| 01/18/2024 | IONS | Buy Now | Ionis Pharmaceuticals | $41.70 | 48.68% | Piper Sandler | Do Kim | $60 → $62 | Maintains | Overweight | Get Alert |
| 01/02/2024 | IONS | Buy Now | Ionis Pharmaceuticals | $41.70 | 48.68% | B of A Securities | Jason Gerberry | $52 → $62 | Upgrade | Neutral → Buy | Get Alert |
| 12/19/2023 | IONS | Buy Now | Ionis Pharmaceuticals | $41.70 | 43.88% | Needham | Joseph Stringer | → $60 | Reiterates | Buy → Buy | Get Alert |
| 12/18/2023 | IONS | Buy Now | Ionis Pharmaceuticals | $41.70 | 19.9% | Stifel | Paul Matteis | $45 → $50 | Maintains | Hold | Get Alert |
| 11/17/2023 | IONS | Buy Now | Ionis Pharmaceuticals | $41.70 | 43.88% | Needham | Joseph Stringer | → $60 | Reiterates | Buy → Buy | Get Alert |
| 11/03/2023 | IONS | Buy Now | Ionis Pharmaceuticals | $41.70 | -32.85% | Goldman Sachs | Salveen Richter | $25 → $28 | Maintains | Sell | Get Alert |
| 11/03/2023 | IONS | Buy Now | Ionis Pharmaceuticals | $41.70 | 15.11% | Morgan Stanley | Michael Ulz | $45 → $48 | Maintains | Equal-Weight | Get Alert |
| 10/23/2023 | IONS | Buy Now | Ionis Pharmaceuticals | $41.70 | 24.7% | B of A Securities | Jason Gerberry | $33 → $52 | Upgrade | Underperform → Neutral | Get Alert |
| 10/05/2023 | IONS | Buy Now | Ionis Pharmaceuticals | $41.70 | 55.88% | RBC Capital | Luca Issi | → $65 | Reiterates | Outperform → Outperform | Get Alert |
| 09/29/2023 | IONS | Buy Now | Ionis Pharmaceuticals | $41.70 | 51.08% | Raymond James | — | → $63 | Initiates | → Strong Buy | Get Alert |
FAQ
What is the target price for Ionis Pharmaceuticals (IONS)?
The latest price target for Ionis Pharmaceuticals (NASDAQ: IONS) was reported by Wolfe Research on April 10, 2024. The analyst firm set a price target for $0.00 expecting IONS to fall to within 12 months (a possible -100.00% downside). 30 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Ionis Pharmaceuticals (IONS)?
The latest analyst rating for Ionis Pharmaceuticals (NASDAQ: IONS) was provided by Wolfe Research, and Ionis Pharmaceuticals upgraded their outperform rating.
When was the last upgrade for Ionis Pharmaceuticals (IONS)?
The last upgrade for Ionis Pharmaceuticals Inc happened on April 10, 2024 when Wolfe Research raised their price target to N/A. Wolfe Research previously had a peer perform for Ionis Pharmaceuticals Inc.
When was the last downgrade for Ionis Pharmaceuticals (IONS)?
The last downgrade for Ionis Pharmaceuticals Inc happened on December 21, 2022 when Morgan Stanley changed their price target from $56 to $40 for Ionis Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Ionis Pharmaceuticals (IONS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ionis Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ionis Pharmaceuticals was filed on April 10, 2024 so you should expect the next rating to be made available sometime around April 10, 2025.
Is the Analyst Rating Ionis Pharmaceuticals (IONS) correct?
While ratings are subjective and will change, the latest Ionis Pharmaceuticals (IONS) rating was a upgraded with a price target of $0.00 to $0.00. The current price Ionis Pharmaceuticals (IONS) is trading at is $42.29, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.